Related Experiment Video
Updated: Aug 21, 2026

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3
Published on: January 24, 2016
Conventional protein kinase C inhibition prevents alpha interferon-mediated hepatitis C virus replicon clearance by
Gian Maria Fimia1, Cristina Evangelisti, Tonino Alonzi
1Gene Expression Laboratory, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Via Portuense 292, 00149 Rome, Italy.
Abstract:
Hepatitis C virus (HCV) has evolved complex strategies to evade host immune responses and establish chronic infection. The only treatment available for HCV infections, alpha interferon (IFN-alpha), is effective in a limited percentage of patients. The mechanisms by which IFN-alpha interferes with the HCV life cycle and the reasons for limited effectiveness of IFN-alpha therapy have not yet been fully elucidated. Using a cell-based HCV replication system and specific kinase inhibitors, we examined the role played by various signaling pathways in the IFN-alpha-mediated HCV clearance. We reported that conventional protein kinase C (cPKC) activity is important for the effectiveness of IFN-alpha treatment. In cells treated with a cPKC-specific inhibitor, IFN-alpha failed to induce an efficient HCV RNA degradation. The lack of cPKC activity leads to a broad reduction of IFN-alpha-stimulated gene expression due to a significant impairment of STAT1 and STAT3 tyrosine phosphorylation. Thus, modulation of cPKC function by either host or viral factors could influence the positive outcome of IFN-alpha-mediated antiviral therapies.
Insights
Conventional protein kinase C (cPKC) activity is crucial for effective Hepatitis C virus (HCV) treatment with alpha interferon (IFN-alpha). Impaired cPKC blocks IFN-alpha
Area of Science:
- Virology
- Immunology
- Cell Biology
Background:
- Hepatitis C virus (HCV) establishes chronic infections by evading host immunity.
- Alpha interferon (IFN-alpha) is an antiviral therapy for HCV but has limited efficacy.
- Mechanisms of IFN-alpha action and treatment failure are not fully understood.
Purpose of the Study:
- To investigate the role of signaling pathways in IFN-alpha-mediated HCV clearance.
- To elucidate the reasons behind the limited effectiveness of IFN-alpha therapy.
Main Methods:
- Utilized a cell-based HCV replication system.
- Employed specific kinase inhibitors to probe signaling pathways.
- Assessed the impact of cPKC inhibition on IFN-alpha treatment efficacy.
Main Results:
- Conventional protein kinase C (cPKC) activity is essential for IFN-alpha to effectively reduce HCV RNA.
- Inhibition of cPKC prevents IFN-alpha-induced HCV RNA degradation.
- Lack of cPKC activity impairs STAT1 and STAT3 tyrosine phosphorylation, reducing IFN-alpha-stimulated gene expression.
Conclusions:
- cPKC signaling is a critical component of the IFN-alpha antiviral response against HCV.
- Modulation of cPKC activity by host or viral factors may impact IFN-alpha therapy outcomes.
- Targeting cPKC could potentially enhance the effectiveness of IFN-alpha-based treatments for HCV.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
The JAK-STAT Signaling Pathway
Inhibitors of Virion Maturation and Assembly
Hepatitis
Viruses with RNA Genomes
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
